Search

Your search keyword '"Uea-Areewongsa, Parichat"' showing total 10 results
Start Over Author "Uea-Areewongsa, Parichat"
10 results on '"Uea-Areewongsa, Parichat"'

1. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand

Author

Mahakkanukrauh, Ajanee, primary, Chaiamnuay, Sumapa, additional, Koolvisoot, Ajchara, additional, Kitamnuayphong, Tassanee, additional, Manavathongchai, Siriporn, additional, Osiri, Manathip, additional, Louthrenoo, Worawit, additional, Uea-areewongsa, Parichat, additional, Ahn, Keumyoung, additional, Jung, Nahyun, additional, Kim, Minkyung, additional, Lee, Seulgi, additional, Kim, Hanna, additional, and Kim, Sunghyun, additional

Published
2023
Full Text
View/download PDF

2. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Author

Adams, Luthando, Ally, Mahmood M, du Plooy, Maria C, Louw, Ingrid C, Nayiager, Savithree, Nel, Christoffel B, Nel, Debra, Reuter, Helmuth, Soloman, Ahmed S, Spargo, Catherine E, Hall, Stephen, Rischmueller, Maureen, Sharma, Shunil D, Will, Robert K, Youssef, Peter P, Arroyo, Caroline, Baes, Rosario P, Dulos, Roger B, Hao, Llewellyn T, Lanzon, Allan E, Lichauco, Juan Javier T, Mangubat, Jill H, Ramiterre, Edgar B, Reyes, Bernadette Heizel M, Tan, Perry P, Choe, Jung-Yoon, Kang, Young Mo, Kwon, Seong Ryul, Lee, Sang-Heon, Lee, Shin-Seok, Yoo, Dae-Hyun, Lin, Hsiao-Yi, Luo, Shue-Fen, Tsai, Shih-Tzu, Tsai, Wen-Chan, Tseng, Jui-Cheng, Wei, Cheng-Chung C, Asavatanabodee, Paijit, Nantiruj, Kanokrat, Nilganuwong, Surasak, Uea-Areewongsa, Parichat, Majstorovic, Ljubinka Bozic, Bacic, Suada Mulic, Batalov, Anastas Z, Georgieva-Slavcheva, Gabriela, Mihailova, Mariyana, Nikolov, Nikolay G, Penev, Dimitar P, Spasov, Yuliy A, Stanimirova, Krasimira, Todorov, Stoyan, Toncheva, Antoaneta R, Yordanova, Nadezhda, Mosterova, Zdenka, Novosad, Libor, Prochazkova, Leona, Stehlikova, Helena, Stejfova, Zuzana, Kiseleva, Natalia, Pank, Lea, Savi, Triin, Alexandra, Balbir-Gurman, Amital, Howard, Mevorach, Dror, Rosner, Itzhak A, Mihailova, Anna, Stumbra-Stumberga, Evija, Basijokiene, Vida, Lietuvininkiene, Virginija, Unikiene, Dalia, Brzezicki, Jan, Dudek, Anna M, Glowacka-Kulesz, Maria B, Grabowicz-Wasko, Barbara, Hajduk-Kubacka, Sabina, Hilt, Joanna, Hrycaj, Pawel, Jeka, Slawomir, Kolasa, Renata, Krogulec, Marek, Mastalerz, Hanna, Olak-Popko, Anna, Owczarek, Elzbieta, Ruzga, Zofia, Walczak, Alina, Ancuta, Codrina I, Ancuta, Ioan, Balanescu, Andra R, Berghea, Florian, Bojin, Silvia, Arvunescu, Mihaela A Ianuli, Ionescu, Ruxandra M, Mociran, Eugenia, Pavel, Mariana, Rednic, Simona, Voie, Adriana, Zainea, Carmen M, Bugrova, Olga V, Demin, Alexander, Ershova, Olga B, Gavrisheva, Inna A, Krechikova, Diana G, Kuropatkin, Gennady V, Marusenko, Irina M, Menshikova, Irina V, Noskov, Sergey M, Rebrov, Andrey P, Smakotina, Svetlana A, Yakushin, Sergey S, Zhilyaev, Evgeny, Ramos, Juan Jose Amarelo, Garcia, Francisco Javier Blanco, Nebro, Antonio Fernandez, Esteban, Silvia Perez, Burson, Juan Miguel Sanchez, Sala, Raimon Sanmarti, Ataman, Sebnem, Hizmetli, Sami, Kuru, Omer, Douglas, Karen M, Emery, Paul, Moots, Robert J, Ong, Voon H, Sheeran, Thomas P, Faraawi, Rafat Y, Lessard, Clode, Mendoza, Carlos Abud, Avila-Armengol, Hilario Ernesto, Zapata, Francisco I Avila, Irazoque-Palazuelos, Fedra Consuelo, Cecena, Marco Antonio Maradiaga, Pacheco-Tena, Cesar F, Rizo-Rodriguez, Juan C, Rodriguez-Torres, Isaura M, Aelion, Jacob A, Caciolo, Barbara A, Calmes, James M, Chatpar, Prem, Dayal, Nimesh, De Jesus, Alex, Dikranian, Ara H, Diri, Erdal, Fairfax, Michael J, Fenton, Ira F, Fleischmann, Roy M, Gaylis, Norman B, George, Ronald L, Halter, Dale G, Hernandez, Paul, Hole, Susan A, Hou, Antony C, Huff, John P, Kafaja, Suzanne, Kennedy, Alastair C, Kenney, Howard, Kimmel, Steven C, Kirby, Brian S, Kivitz, Alan J, Legerton, Clarence W, Lindsey, Stephen M, Mallepalli, Jyothi R, Mathews, Steven D, Metyas, Samy K, Mizutani, Wesley T, Najam, Sabeen, Nascimento, Joao M, Pang, Shirley W, Patel, Rakesh C, Poiley, Jeffrey E, Ramirez, Carlos E, Reddy, Riteesha, Rehman, Qaiser, Schnitz, William M, Scoville, Craig D, Shergy, William J, Silverfield, Joel C, Singhal, Atul K, Smallwood-Sherrer, Yvonne R, Songcharoen, Suthin N, Stack, Michael T, Stohl, William, Su, Tien-I K, Udell, James, Waraich, Saleem, Weidmann, Charles E, Wei, Nathan, Wiesenhutter, Craig W, Winkler, Anne E, Zagar, Karen E, Berman, Alberto, Mysler, Eduardo F, Hidalgo, Rodolfo A Pardo, Venarotti, Horacio O, Sariego, Irmgadt Annelise Goecke, Calabresse, Renato E Jimenez, Ruiz-Tagle, Juan Ignacio Vargas, Vargas, Luis Fernando M Bellatin, Berrocal, Alfredo E, Portocarrero, Manuel Gustavo Leon, Jesus, Felix, Pena, Romero, Fleischmann, Roy, Mysler, Eduardo, Luo, Zhen, DeMasi, Ryan, Soma, Koshika, Zhang, Richard, Takiya, Liza, Tatulych, Svitlana, Mojcik, Christopher, Krishnaswami, Sriram, Menon, Sujatha, and Smolen, Josef S

Published
2017
Full Text
View/download PDF

4. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis

Author

Louthrenoo, Worawit, Kasitanon, Nuntana, Katchamart, Wanruchada, Aiewruengsurat, Duangkamol, Chevaisrakul, Parawee, Chiowchanwisawakit, Praveena, Dechanuwong, Pornchai, Hanvivadhanakul, Punchong, Mahakkanukrauh, Ajanee, Manavathongchai, Siriporn, Muangchan, Chayawee, Narongroeknawin, Pongthorn, Phumethum, Veerapong, Siripaitoon, Boonjing, Suesuwan, Anawat, Suwannaroj, Siraphop, Uea‐Areewongsa, Parichat, Ukritchon, Sittichai, Asavatanabodee, Paijit, Koolvisoot, Ajchara, Nanagara, Ratanavadee, Totemchokchyakarn, Kitti, Nuntirooj, Kanokrut, and Kitumnuaypong, Tasanee

Published
2017
Full Text
View/download PDF

7. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Author

Fleischmann, Roy, primary, Mysler, Eduardo, additional, Hall, Stephen, additional, Kivitz, Alan J, additional, Moots, Robert J, additional, Luo, Zhen, additional, DeMasi, Ryan, additional, Soma, Koshika, additional, Zhang, Richard, additional, Takiya, Liza, additional, Tatulych, Svitlana, additional, Mojcik, Christopher, additional, Krishnaswami, Sriram, additional, Menon, Sujatha, additional, Smolen, Josef S, additional, Adams, Luthando, additional, Ally, Mahmood M, additional, du Plooy, Maria C, additional, Louw, Ingrid C, additional, Nayiager, Savithree, additional, Nel, Christoffel B, additional, Nel, Debra, additional, Reuter, Helmuth, additional, Soloman, Ahmed S, additional, Spargo, Catherine E, additional, Rischmueller, Maureen, additional, Sharma, Shunil D, additional, Will, Robert K, additional, Youssef, Peter P, additional, Arroyo, Caroline, additional, Baes, Rosario P, additional, Dulos, Roger B, additional, Hao, Llewellyn T, additional, Lanzon, Allan E, additional, Lichauco, Juan Javier T, additional, Mangubat, Jill H, additional, Ramiterre, Edgar B, additional, Reyes, Bernadette Heizel M, additional, Tan, Perry P, additional, Choe, Jung-Yoon, additional, Kang, Young Mo, additional, Kwon, Seong Ryul, additional, Lee, Sang-Heon, additional, Lee, Shin-Seok, additional, Yoo, Dae-Hyun, additional, Lin, Hsiao-Yi, additional, Luo, Shue-Fen, additional, Tsai, Shih-Tzu, additional, Tsai, Wen-Chan, additional, Tseng, Jui-Cheng, additional, Wei, Cheng-Chung C, additional, Asavatanabodee, Paijit, additional, Nantiruj, Kanokrat, additional, Nilganuwong, Surasak, additional, Uea-Areewongsa, Parichat, additional, Majstorovic, Ljubinka Bozic, additional, Bacic, Suada Mulic, additional, Batalov, Anastas Z, additional, Georgieva-Slavcheva, Gabriela, additional, Mihailova, Mariyana, additional, Nikolov, Nikolay G, additional, Penev, Dimitar P, additional, Spasov, Yuliy A, additional, Stanimirova, Krasimira, additional, Todorov, Stoyan, additional, Toncheva, Antoaneta R, additional, Yordanova, Nadezhda, additional, Mosterova, Zdenka, additional, Novosad, Libor, additional, Prochazkova, Leona, additional, Stehlikova, Helena, additional, Stejfova, Zuzana, additional, Kiseleva, Natalia, additional, Pank, Lea, additional, Savi, Triin, additional, Alexandra, Balbir-Gurman, additional, Amital, Howard, additional, Mevorach, Dror, additional, Rosner, Itzhak A, additional, Mihailova, Anna, additional, Stumbra-Stumberga, Evija, additional, Basijokiene, Vida, additional, Lietuvininkiene, Virginija, additional, Unikiene, Dalia, additional, Brzezicki, Jan, additional, Dudek, Anna M, additional, Glowacka-Kulesz, Maria B, additional, Grabowicz-Wasko, Barbara, additional, Hajduk-Kubacka, Sabina, additional, Hilt, Joanna, additional, Hrycaj, Pawel, additional, Jeka, Slawomir, additional, Kolasa, Renata, additional, Krogulec, Marek, additional, Mastalerz, Hanna, additional, Olak-Popko, Anna, additional, Owczarek, Elzbieta, additional, Ruzga, Zofia, additional, Walczak, Alina, additional, Ancuta, Codrina I, additional, Ancuta, Ioan, additional, Balanescu, Andra R, additional, Berghea, Florian, additional, Bojin, Silvia, additional, Arvunescu, Mihaela A Ianuli, additional, Ionescu, Ruxandra M, additional, Mociran, Eugenia, additional, Pavel, Mariana, additional, Rednic, Simona, additional, Voie, Adriana, additional, Zainea, Carmen M, additional, Bugrova, Olga V, additional, Demin, Alexander, additional, Ershova, Olga B, additional, Gavrisheva, Inna A, additional, Krechikova, Diana G, additional, Kuropatkin, Gennady V, additional, Marusenko, Irina M, additional, Menshikova, Irina V, additional, Noskov, Sergey M, additional, Rebrov, Andrey P, additional, Smakotina, Svetlana A, additional, Yakushin, Sergey S, additional, Zhilyaev, Evgeny, additional, Ramos, Juan Jose Amarelo, additional, Garcia, Francisco Javier Blanco, additional, Nebro, Antonio Fernandez, additional, Esteban, Silvia Perez, additional, Burson, Juan Miguel Sanchez, additional, Sala, Raimon Sanmarti, additional, Ataman, Sebnem, additional, Hizmetli, Sami, additional, Kuru, Omer, additional, Douglas, Karen M, additional, Emery, Paul, additional, Ong, Voon H, additional, Sheeran, Thomas P, additional, Faraawi, Rafat Y, additional, Lessard, Clode, additional, Mendoza, Carlos Abud, additional, Avila-Armengol, Hilario Ernesto, additional, Zapata, Francisco I Avila, additional, Irazoque-Palazuelos, Fedra Consuelo, additional, Cecena, Marco Antonio Maradiaga, additional, Pacheco-Tena, Cesar F, additional, Rizo-Rodriguez, Juan C, additional, Rodriguez-Torres, Isaura M, additional, Aelion, Jacob A, additional, Caciolo, Barbara A, additional, Calmes, James M, additional, Chatpar, Prem, additional, Dayal, Nimesh, additional, De Jesus, Alex, additional, Dikranian, Ara H, additional, Diri, Erdal, additional, Fairfax, Michael J, additional, Fenton, Ira F, additional, Fleischmann, Roy M, additional, Gaylis, Norman B, additional, George, Ronald L, additional, Halter, Dale G, additional, Hernandez, Paul, additional, Hole, Susan A, additional, Hou, Antony C, additional, Huff, John P, additional, Kafaja, Suzanne, additional, Kennedy, Alastair C, additional, Kenney, Howard, additional, Kimmel, Steven C, additional, Kirby, Brian S, additional, Legerton, Clarence W, additional, Lindsey, Stephen M, additional, Mallepalli, Jyothi R, additional, Mathews, Steven D, additional, Metyas, Samy K, additional, Mizutani, Wesley T, additional, Najam, Sabeen, additional, Nascimento, Joao M, additional, Pang, Shirley W, additional, Patel, Rakesh C, additional, Poiley, Jeffrey E, additional, Ramirez, Carlos E, additional, Reddy, Riteesha, additional, Rehman, Qaiser, additional, Schnitz, William M, additional, Scoville, Craig D, additional, Shergy, William J, additional, Silverfield, Joel C, additional, Singhal, Atul K, additional, Smallwood-Sherrer, Yvonne R, additional, Songcharoen, Suthin N, additional, Stack, Michael T, additional, Stohl, William, additional, Su, Tien-I K, additional, Udell, James, additional, Waraich, Saleem, additional, Weidmann, Charles E, additional, Wei, Nathan, additional, Wiesenhutter, Craig W, additional, Winkler, Anne E, additional, Zagar, Karen E, additional, Berman, Alberto, additional, Mysler, Eduardo F, additional, Hidalgo, Rodolfo A Pardo, additional, Venarotti, Horacio O, additional, Sariego, Irmgadt Annelise Goecke, additional, Calabresse, Renato E Jimenez, additional, Ruiz-Tagle, Juan Ignacio Vargas, additional, Vargas, Luis Fernando M Bellatin, additional, Berrocal, Alfredo E, additional, Portocarrero, Manuel Gustavo Leon, additional, Jesus, Felix, additional, and Pena, Romero, additional

Published
2017
Full Text
View/download PDF

9. Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases.

Author

Uea-Areewongsa P, Pinpathomrat N, Ongarj J, Sophonmanee R, Seepathomnarong P, Seeyankem B, Surasombatpattana S, and Intapiboon P

Abstract

Background: Alongside vaccine hesitancy, impaired and waning immunity in autoimmune rheumatic diseases (ARDs) are barriers to immunization. The timeframe of immunity waning in ARD remains unclear., Objective: We aimed to examine the waning of humoral immunogenicity in a cohort of ARD patients who received the heterologous inactivated vaccine followed by the adenoviral vector SAR-CoV-2 vaccine at a 3-month follow-up., Methods: The levels of SARS-CoV-2 anti-RBD IgG were evaluated at 1 and 3 months in adults with ARDs (n = 29) and age- and sex-matched healthy controls (HC) that received the heterologous prime-boost CoronaVac vaccine followed by the ChAdOx1 nCoV-19 vaccine. Seropositivity was defined as anti-receptor binding domain (RBD) IgG levels of ≥ 7.15 binding antibody units (BAU)/mL. The kinetic properties of the vaccines were evaluated based on the ratio of anti-RBD IgG values obtained at each follow-up. Disease activity was evaluated., Results: The seropositivity rate was lower among patients with ARDs than among HCs (89.7% vs. 100%, p = 0.237). At 3 months, the median (IQR) anti-RBD IgG level was lower among patients with ARDs than among HCs (122.3 [30.6, 247.8] vs. 294.2 [127.4,605.7] BAU/mL, p = 0.006). Mean antibody levels in patients with ARDs decreased 3.5 (1.9)-fold within 3 months post-vaccination (122.3 [30.6, 247.8] vs. 279.9 [86,1076.5] BAU/mL, p < 0.001). Disease flare-ups occurred in three patients., Conclusions: Our findings included changes to anti-RBD IgG levels and may inform vaccination strategies. SAR-CoV2 vaccine-induced immunity was lower in patients with ARDs than in HCs and decreased within 3 months, suggesting a need for booster vaccinations.

Published
2023
Full Text
View/download PDF

10. Factors associated with osteonecrosis in Thai lupus patients: a case control study.

Author

Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, and Asavatanabodee P

Subjects
Adult, Antimalarials therapeutic use, Case-Control Studies, Female, Femur Head Necrosis prevention & control, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Kidney physiopathology, Logistic Models, Lupus Erythematosus, Systemic drug therapy, Male, Retrospective Studies, Thailand, Femur Head Necrosis ethnology, Femur Head Necrosis etiology, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic ethnology
Abstract

Objective: To identify associated factors for the development of osteonecrosis of a femoral head (ON) in patients with systemic lupus erythematosus (SLE)., Methods: We conducted a retrospective nested case-control study from SLE patients who attended the Rheumatology Clinic at Phramongkutklao Hospital from 1992-2008. Cases were defined as SLE patients, who had clinically apparent ON (confirmed by plain radiographs or magnetic resonance imaging). For each case, a control was selected and matched to the case by age and disease duration. The main outcome measure was the odds ratio (OR) of ON among SLE patients. The clinical and laboratory variables thought to be risk factors of ON variables were compared between patients who did and did not develop ON. Significant and clinically relevant variables were then examined by a stepwise logistic regression model., Results: Of 186 SLE patients, we identified 41 patients who developed ON during the course of follow-up. Twenty patients were available for data analysis. From the univariate analysis, incidence of renal involvement and the use of steroids (recorded as evidenced by maximum and mean daily prednisolone dose) were significantly higher in the ON group than in controls. The use of antimalarials was significantly lower in patients with ON than in controls. No difference in disease activity, lipid profiles or anticardiolipin antibody was found between groups. In the logistic regression, the presence of renal involvement remained as a positive associated factor for ON (OR = 7.80, CI = 1.249-48.748, P = 0.028) and the use of antimalarial drugs was a negative associated factor for ON (OR = 0.09, CI = 0.009-0.961, P = 0.046)., Conclusion: The presence of renal involvement was associated with ON and the antimalarial use may have a protective effect for ON in Thai patients with SLE. The findings from this study further support the use of antimalarial drugs in SLE patients.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results